Second allogenetic SCT for ALL – pro
here are large retrospective studies, but no prospective studies, even for ALL. Thus, there are no published peer-reviewed data from well-constructed clinical studies to permit scientific conclusion regarding the benefit and improved health outcomes with a second Allogeneic stem cell transplant for an individual with a diagnosis of this Lymphoma.
F.E. Poon reported 21 patients who received a 2nd transplant in ALL and 75% obtained a CR. With a median follow-up of 3 years, 1- and 3-year PFS was 23 and 11% and 1- and 3 year OS rates were 23 and 11%. Nagler studied 245 patients and The 2- and 5-year cumulative incidence of non-relapse mortality, relapse incidence, leukaemia-free survival, overall survival and GVHD-free, relapse-free survival (GRFS) were 24% and 26%, 56% and 62%, 20% and 12%, 30% and 14% and 12% & 7%, respectively. I
Poon LM, Bassett R Jr, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant. 2013 May; 48(5): 666-70. doi: 10.1038/by.2012.195. Epub 2012 Oct 22. PMID: 23085830.
Nagler A, Labopin M, et al, Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Br J Haematol. 2019 Sep; 186(5): 767-776.